Liver News and Research

RSS

Amorfix second quarter net loss decreases to $25,728

Amorfix Life Sciences, a product development company focused on the development of diagnostics and therapeutics for misfolded protein diseases, today announced its operational and financial results for the three and six months ended September 30, 2010.

12 Nov 2010

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Pro-Pharmaceuticals, Inc., a developer of therapeutics that target Galectin receptors to treat cancer and fibrosis, today reported its financial results for the third quarter and the nine months ended September 30, 2010. These results are included in the Company's Quarterly Report on Form 10-Q, which has been filed with the SEC.

12 Nov 2010

Dreaded cod liver oil in a variety of flavours

The stomachs of the generation of 50 year olds and above, will be churning at the thought of their parents and grandparents serving up spoonfuls of the much dreaded cod liver oil. As a practice, parents giving their children cod liver oil has all but died, and yet, as a population, we have seen more and more inflammatory conditions effect people's lives, which are due in no small part to the 'modern day diet', which many of us live.

12 Nov 2010

Scientists unveil mechanism of liver regeneration

The liver's unique ability among organs to regenerate itself has been little understood. Now Weill Cornell Medical College scientists have shed light on how the liver restores itself by demonstrating that endothelial cells the cells that form the lining of blood vessels play a key role.

12 Nov 2010

Microsulis reports additional IEC electrical safety clearances for Accu2i pMTA system

Microsulis reports that the groundbreaking Accu2i pMTA system for destroying unwanted tissue and used in the treatment of liver and other cancers now carries an impressive range of electrical safety standards. The Accu2i is CE-marked and carries FDA 510(k) clearance and so is cleared for electrical safety and performance with the internationally recognised standard IEC 60601-1 for electrical safety.

12 Nov 2010

Alcohol damages liver, weakens immune system, slows healing, impairs bone formation, and much more

Alcohol does much more harm to the body than just damaging the liver. Drinking also can weaken the immune system, slow healing, impair bone formation, increase the risk of HIV transmission and hinder recovery from burns, trauma, bleeding and surgery.

12 Nov 2010

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

Researchers report that a drug commonly used to treat diabetes may also retard the growth of fluid-filled cysts of the most common genetic disorder, polycystic kidney disease.

12 Nov 2010

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

Celsion Corporation, a leading oncology drug development company, today announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has issued a positive opinion on the application for Orphan Drug Designation for ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, for the treatment of hepatocellular carcinoma (HCC), commonly referred to as primary liver cancer.

12 Nov 2010

HemaCAM computer-assisted blood cell analysis system automates assessment of blood counts

If a blood count is abnormal, the medical laboratory scientist (MLS) has to manually perform a differential blood count analysis. This costs time and money. The computer-assisted blood cell analysis system HemaCAM by the company Horn has recently been launched on the market and does just this. At the MEDICA 2010 trade fair, which is being held from November 17 to 20 in Düsseldorf, Germany, scientists from the Fraunhofer Institute for Integrated Circuits IIS will be presenting this intelligent microscopy system at joint stand F05 in hall 10.

11 Nov 2010

New findings suggest serotonin may have anti-diabetic property

New findings by researchers at UT Southwestern Medical Center suggest that serotonin a brain chemical known to help regulate emotion, mood and sleep might also have anti-diabetic properties.

11 Nov 2010

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Diabetics can face a five times increase in the risk of developing cardiovascular disease (CVD) than non-diabetics. This leads to a seven to ten year reduction in life expectancy and a higher probability of suffering a fatal heart attack. These sad statistics have prompted the European Society of Cardiology (ESC) to mark World Diabetes Day on 14 November 2010 by emphasising the simple measures that diabetes patients should adopt to slow-down the progression of CVD and greatly improve their quality of life.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Children with hepatitis C fare decidedly better with a supercharged combination of two antiviral drugs than with the usual and standard single-drug regimen, according to research led by investigators at the Johns Hopkins Children Center.

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Egrifta receives FDA approval for treatment of HIV-lipodystrophy

The U.S. Food and Drug Administration today approved Egrifta (tesamorelin) to treat HIV patients with lipodystrophy, a condition in which excess fat develops in different areas of the body, most notably around the liver, stomach, and other abdominal organs. The condition is associated with many antiretroviral drugs used to treat HIV.

10 Nov 2010

NCI awards $4 million for UNM's cancer nanotechnology partnership with Sandia Labs

The National Cancer Institute recently announced two five-year awards totaling nearly $4 million for a partnership between the University of New Mexico Cancer Center and Sandia National Laboratories. One $1.95 million grant will fund the creation of a joint Cancer Nanotechnology Platform Partnership, and another $1.8 million grant will pay for a new Cancer Nanotechnology Training Center to train a new generation of multidisciplinary scientists.

10 Nov 2010

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the European Medicines Agency (EMA) granted orphan product designation for SBC-102 (Recombinant Human Lysosomal Acid Lipase), the Company's enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency.

10 Nov 2010

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Examining the blood "metabolomics" profile of smokers immediately after they had a cigarette revealed activation of pathways involved in cell death, inflammation, and other forms of systemic damage, say researchers at Georgetown Lombardi Comprehensive Cancer Center, part of Georgetown University Medical Center.

9 Nov 2010

Colcrys safe for treating gout flares

Patients who experience gout flares can be treated safely with Colcrys (colchicine, USP), even in the presence of co-morbid conditions that often present physicians with treatment challenges, according to a new analysis presented here at the 74th Annual Scientific Meeting of the American College of Rheumatology (ACR).

9 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

Liver News and Research

Amorfix second quarter net loss decreases to $25,728

Pro-Pharmaceuticals third quarter net loss decreases to $1,899,000

Dreaded cod liver oil in a variety of flavours

Scientists unveil mechanism of liver regeneration

Microsulis reports additional IEC electrical safety clearances for Accu2i pMTA system

Alcohol damages liver, weakens immune system, slows healing, impairs bone formation, and much more

Diabetic drug may retard growth of fluid-filled cysts in PKD: Research

COMP issues positive opinion for Celsion's ThermoDox Orphan Drug Designation

HemaCAM computer-assisted blood cell analysis system automates assessment of blood counts

New findings suggest serotonin may have anti-diabetic property

ESC emphasizes simple measures for diabetic patients to slow-down CVD progression

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Combination of antiviral drugs outperforms single-drug therapy in children with hepatitis C

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Egrifta receives FDA approval for treatment of HIV-lipodystrophy

NCI awards $4 million for UNM's cancer nanotechnology partnership with Sandia Labs

Synageva's SBC-102 enzyme replacement therapy for LAL deficiency granted European orphan product designation

Blood 'metabolomics' study uncovers liver, heart, and kidney toxicity in healthy smokers

Colcrys safe for treating gout flares

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News